After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.
Psychedelics, Solid Tumors Will Be Key Focuses for Investors in 2024 Read More »
Examining 50 existing drugs, researchers find that the IRA could cause drug developers to shy away from pursuing subsequent indications for their marketed drugs, thereby reducing the number of new approvals.
Drug Price Negotiations Could Discourage Additional Approvals: Study Read More »
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
Biopharma Mergers and Acquisitions Continue to Trend Upward in 2024 Read More »
Provider groups said the government should go further to financially bolster providers during the outage at Change Healthcare.
CMS rolls out provider flexibilities amid fallout from Change cyberattack Read More »
The Oakland, Calif.-based nonprofit health system continues to downsize its tech department in a bid to increase efficiencies and cut costs.
Kaiser lays off IT workers for a second time in 4 months Read More »
Attune’s device to help cool the esophagus during radiofrequency ablation procedures is a key piece of the acquisition.
The company confirmed the potential job reductions from shutting down its ventilator product lines in an email to MedTech Dive.
Medtronic estimates up to 40 job losses in Ireland due to restructuring Read More »
It’s a positive development for the insurer, which sued the government earlier this year after its quality scores fell dramatically.
Gossamer Bio, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.
The American Hospital Association and the American Medical Association pushed the federal government to offer more financial support as the outage limits providers’ ability to receive payment.
Provider groups urge HHS, Congress to mitigate damage from Change cyberattack Read More »
